Provident Financial Services, Inc.· PFS

RPX Gold Expands Gold Mineralization Beyond the PEA Open Pit and Underground Mine in Support of the Planned PFS

TORONTO--(BUSINESS WIRE)---- $RPX.V #Canada--RPX Gold Inc. (“RPX Gold” or the “Company”) (TSXV: RPX) (OTCQB: RDEXF) is pleased to announce gold (“Au”) assay results from 25 drill holes totalling 4,336 metres (“m”) from its 2026 ongoing drilling program at the Wawa Gold Project in Ontario. The Company has now completed approximately two-thirds of the drilling meterage planned to support the prefeasibility study (“PFS”) and approximately half of its planned 20,000 m 2026 drill program. The results will be included.

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu

Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. [url="]announced[/url] that updated data, including overall survival (OS), from

REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial e

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

Johnson and Johnson's RYBREVANTÂ (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positi

Provident Financial price target raised to $21 from $18 at RBC Capital

Piper Sandler Reiterates Overweight Rating on Provident Financial Services (PFS)

DA Davidson Upgrades Provident Financial Services (PFS) to Buy

Provident Financial price target lowered to $18 from $19 at RBC Capital

Provident Financial price target lowered to $15 from $17 at DA Davidson